The development and characterization of a human mesothelioma in Vitro 3D model to investigate immunotoxin therapy

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Xiang, Xinran ^a   Phung, Yen ^a   Feng, Mingqian ^a   Nagashima, Kunio ^b   Zhang, Jingli ^a   Courtney Broaddus, V ^c   Hassan, Raffit ^a   FitzGerald, David ^a   Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; IMMUNOTOXIN SS1P; MESOTHELIN; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; ANTIBODY; CADHERIN; MONOCLONAL ANTIBODY; SS1(DSFV)PE38;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; ELECTRON MICROSCOPY; FLUORESCENCE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MESOTHELIOMA; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SPHEROID CELL; THREE DIMENSIONAL IMAGING; TIGHT JUNCTION; TUMOR MICROENVIRONMENT; CULTURE TECHNIQUE; IMMUNOLOGY; KINETICS; METHODOLOGY; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL CULTURE;

BACTERIA (MICROORGANISMS);

ANTIBODIES; ANTIBODIES, MONOCLONAL; CADHERINS; CELL CULTURE TECHNIQUES; HUMANS; IMMUNOTOXINS; KINETICS; MESOTHELIOMA; MICROSCOPY, ELECTRON; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 79551621653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014640     Document Type: Article

References (35)

1. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241-263.
2. Desoize B, Jardillier J (2000) Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36: 193-207.
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
4. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis - A link between cancer genetics and chemotherapy. Cell 108: 153-164.
5. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431.
6. Pampaloni F, Reynaud EG, Stelzer EH (2007) The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845.
7. Lechner JK, Tokiwa T, LaVeck M, Benedict WF, Banks-Schlegel S, et al. (1985) Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A 82: 3884-3888.
8. Wang Y, Zhao R, Chattopadhyay S, Goldman ID (2002) A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate pemetrexed. Cancer Res 62: 6434-6437.
9. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC (1998) Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol Lung Cell Mol Physiol 275: 165-171.
10. Steele J, Klabatsa A, Fennell DA, Pallaeska A, Sheaff MT, et al. (2005) Prognostic factors in mesothelioma. Lung Cancer 49: S49-52.
11. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283: 13021-13030.
12. Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53.
13. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13: 1571-1575.
14. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, et al. (2008) Comparison of osteopontin, megakaryocyte potentiating factor, and Mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3: 851-857.
15. Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, et al. (2009) A binding domain on mesothelin for CA125/MUC16. J Biol Chem 284: 3739-3749.
16. Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, et al. (2009) Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ 16: 1146-1155.
17. Marchevsky AM (2008) Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132: 397-401.
18. Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, et al. (2006) Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 19: 514-523.
19. Oury TD, Hammar SP, Roggli VL (1998) Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 29: 1382-1392.
20. Contreras RG, Shoshani L, Flores-Maldonado C, Lazaro A, Monroy AO, et al. (2002) E-Cadherin and tight junctions between epithelial cells of different animal species. Eur J Physiol 444: 467-475.
21. Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, et al. (2004) Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 103: 2718-2726.
22. Yang TM, Barbone D, Fennell DA, Broaddus VC (2009) Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 41: 14-23.
23. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, et al. (2006) Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 12: 4695-4701.
24. Zhang Y, Xiang L, Hassan R, Pastan I (2007) Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 104: 17099-17104.
25. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J (2007) Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 13: 7166-7171.
26. Zhang Y, Pastan I (2008) High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 14: 7981-7986.
27. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, et al. (2010) A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 70: 1082-1089.
28. Green SK, Francia G, Isidoro C, Kerbel RS (2004) Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 3: 149-159.
29. Lin RZ, Chou LF, Chien CC, Chang HY (2006) Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and beta1-integrin. Cell Tissue Res 324: 411-422.
30. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, et al. (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66: 1526-35.
31. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ (2008) Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 68: 4398-4405.
32. Du X, Youle RJ, Fitzgerald DJ, Pastan I (2010) Pseudomonas Exotoxin Amediated Apoptosis is Bak-dependent and Preceded by the Degradation of Mcl-1. Mol Cell Biol 30: 3444-3452.
33. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
34. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A (1999) E-Cadherin, Ncadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol 20: 125-130.
35. Kitazume H, Kitamura K, Mukai K, Inayama Y, Kawano N, et al. (2000) Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-Cadherin and calretinin immunostaining. Cancer 90: 55-60.